The aim of this study was to evaluate treatment results for HL patients younger than 60 years in stage IIB, treated according to the Swedish National Care Programme. The intention was also to identify specific subgroups depending on the number of negative prognostic factors the patients have, in order to optimise and differentiate future treatment. In total, 99 patients with HL stage IIB, diagnosed between 1985 and 1994, have been analysed. There were 47 men and 52 women and the median age was 33 years (range 17-59). Eighty-six patients presented with supradiaphragmatic disease and 13 with infradiaphragmatic. The HL specific and overall 10-year survival was 73% and 65%, respectively. The HL specific survival for patients in pathological stage IIB tended to be better, although not statistically significant than for clinical stage IIB, despite less chemotherapy (p=0.1). The patients in stage IIB who were selected for laparotomy were, however, younger and with fewer negative prognostic factors. The only significant negative prognostic factor was bulky disease (p=0.001). The following factors also tended to have a negative influence on the prognosis although not statistically significant: the International Prognostic Score, the number of involved lymph node stations, extranodal involvement, and leukocyte count > 15x10 9 /L. In conclusion, we suggest that bulky disease should be taken into account when treating patients with stage IIB HL.
INTRODUCTION
Bulky disease was defined as a mediastinal mass ratio greater than 0.33 of the thorax diameter at the Th. 5-6 level or a lymph node region with a diameter greater than 10 cm. Extreme bulky disease was defined as a ratio greater than 0.45. The number of lymph node regions with HL-engagement was also defined and varied between 2 and 9. Involvement of both hili and the mediastinum were defined as three locals. The patients were divided into groups with 2, 3, and 4 or more involved sites.
Statistical methods
The Chi 2 test was used to compare differences in proportions between groups. The survival curves were calculated according to the method of Kaplan and Meier. Log-rank test was used to compare survival in two groups. Cox proportional hazard regression model was used to test the laboratory parameters. Since some data are missing, the analyses are based on the patients with complete data sets relevant to the specific analyses performed.
Disease-free survival (DFS) was defined as the time from diagnosis to relapse or death from HL.
The patients who never reached CR had a DFS of zero days. Patients that were disease-free at the last follow up and patients dead by other reasons than HL in CR were censored. HL-specific survival was defined as the time from diagnosis to death from or with HL.
RESULTS
The clinical characteristics of the 99 patients are given in tables 1 and 2. Eighty-six patients had supradiaphragmatic disease (table 1) and 13 had infradiaphragmatic disease (table 2). These two groups are presented separately because they often have different clinical presentations and natural history (Amini et al., 2002; Kalkner et al., 1997) .
Supradiaphragmatic disease
The treatment results for patients with supradiaphragmatic disease are shown in table 3. In 16 patients staging laparotomy was performed. These patients were slightly younger than those in CS IIB (median age 27 versus 34 years). Six (38%) of these patients had bulky disease (compared to 49/70 (70%) for CS IIB, p=0.01), but none had extreme bulky disease. Only one patient had an extranodal lesion and it was not noticed until after therapy had been started. All patients achieved a CR. Two patients received RT alone. One patient was initially evaluated as stage IB, achieved a CR and no chemotherapy was given. For the second patient there is no explanation of the choice of treatment and this patient later relapsed in a new local.
The two patients that relapsed out of the 14 treated with 2 cycles of chemotherapy + RT both had bulky disease. One of the relapses was at the border of the radiation field and the other one was a generalised relapse both inside and outside of the area treated with radiotherapy.
Seventy patients were in CS IIB and the treatment results are presented in table 2. The four patients who did not achieve a CR all had initially bulky disease and died of HL. Twenty-two (31%) patients have relapsed and 17 of them had bulky disease. Five of these 17 patients relapsed within previously irradiated areas. Relapse treatment was chemotherapy, mostly ABVD or MIME, followed by highdose chemotherapy and autologous stem cell transplantation (ABMT) in 10 patients. Seven patients have experienced a new relapse and six died of HL. Additionally, one patient died from pneumonitis.
The reasons for not treating 7 patients with ABMT were i n two cases patient refusal, both subsequently died of HL; in one case rapid progression and death, in one death from acute myeloic leukemia, in one patient death from pneumocystis carinii infection, in one patient data is missing (dead of HL), and one patient was treated with chemotherapy alone and there is no explanation why infradiaphragmatic disease also support other studies (Kalkner et al., 1997) showing that the prognosis is not worse than for the ones with supradiaphragmatic disease.
In this study we have described all patients in 5 out of 6 regions in Sweden diagnosed with stage IIB HL from 1985 to 1994. The results seem comparable to those seen at specialised centres treated during the same time period (Glick et al., 1998 , Haesenclever & Diehl, 1998 (Diehl et al., 1997) in this subgroup of patients has been investigated in the GHSG HD9 trial. The study was intended for advanced HL but patients with stage IIB, bulky disease were included. The patients were randomised between 4 COPP/ABVD, 8 BEACOPP baseline or 8 BEACOPP escalated followed by limited radiation. The study showed superiority for the BEACOPP and this concept is currently explored further in the HD12 study (Franklin &Diehl, 2002) . 
